Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,875 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: fast Clear all
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Nov 13, 2026, 6:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Respiratory Muscle Function in Heart Failure

NCT03924479
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
PowerBreathe (Breathing muscle training)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 13, 2026, 6:45 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Mechanisms of Hypoglycemia in Patients Without Diabetes

NCT04428723
View directory record Official record
Conditions
Hypoglycemia
Interventions
Entry of demographic and medical history data into a deidentified database, Blood sample for DNA analysis, Stool sample for microbiome analysis, Mixed meal tolerance test, Continuous glucose monitoring, activity monitor
Other · Genetic · Diagnostic Test
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 13, 2026, 6:45 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Rapid Vaccination of Hard-To-Reach Populations

NCT00155974
View directory record Official record
Conditions
Influenza
Interventions
Community-based vaccine outreach intervention
Biological
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Nov 13, 2026, 6:45 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Proof-of-concept Study on Rapid Immune Modulating Effects

NCT05364710
View directory record Official record
Conditions
Immune Surveillance
Interventions
Transfer factor from colostrum ultrafiltrate
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Nov 13, 2026, 6:45 AM EST
Completed Not applicable Interventional

OPTIMIzing muScle Preservation in paTients wIth Cirrhosis

NCT05367596
View directory record Official record
Conditions
Obesity, Compensated Cirrhosis, Sarcopenia
Interventions
Continuous Energy Restriction (CER), Alternate Day Modified Fasting (ADMF), Group Health Education Sessions, Late Evening Snack, Physical activity, Self-monitoring, Remotely Supervised Exercise Sessions
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Nov 13, 2026, 6:45 AM EST
Completed No phase listed Observational

Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma

NCT04205708
View directory record Official record
Conditions
Silicosis, Pneumoconiosis; Silica
Interventions
Tuberculosis test, Chest X-ray, Pulmonary Function Test
Diagnostic Test
Lead sponsor
University of Oklahoma
Other
Eligibility
30 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Nov 13, 2026, 6:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lidocaine Administration Using STAR Particles

NCT06034340
View directory record Official record
Conditions
Anesthesia, Local
Interventions
LET Gel after STAR Particle Application (Right or Left Arm), LET Gel Application without STAR Particle Application (Contralateral Arm)
Device · Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Nov 13, 2026, 6:45 AM EST
Completed Phase 4 Interventional Results available

Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation

NCT03545503
View directory record Official record
Conditions
Intubation Complication
Interventions
Etomidate, Ketamine
Drug
Lead sponsor
South East Area Health Education Center, Wilmington, NC
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Nov 13, 2026, 6:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Time-restricted Eating Acceptability, Efficacy and Safety in Obesity

NCT06695988
View directory record Official record
Conditions
Time Restricted Eating, Obesity
Interventions
Time Restricted Eating
Behavioral
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Oxford, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 13, 2026, 6:45 AM EST
Recruiting No phase listed Observational

GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound

NCT07251803
View directory record Official record
Conditions
Gastric Retention
Interventions
Gastric Ultrasound
Diagnostic Test
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 13, 2026, 6:45 AM EST
Terminated Phase 2 Interventional Results available

Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

NCT03287050
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, SBRT
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Nov 13, 2026, 6:45 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

NCT05367661
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CHK336, Placebo
Drug
Lead sponsor
Chinook Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Nov 13, 2026, 6:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Graded Insulin Suppression Test P&F

NCT06592261
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions
Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 13, 2026, 6:45 AM EST
Completed Phase 3 Interventional Results available

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

NCT01336023
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
146
States / cities
Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Nov 13, 2026, 6:45 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Light Driven Analgesia

NCT07245303
View directory record Official record
Conditions
Musculoskeletal Pain, Fibromyalgia, Healthy Controls Group - Age and Sex-matched
Interventions
S-cone modulating visual stimulus, Equal Energy White Visual Stimulus, Green light visual stimulus (S-OFF), Evoked Pressure Pain Stimulus
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 13, 2026, 6:45 AM EST
Completed Phase 4 Interventional Results available

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

NCT01779869
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Nov 13, 2026, 6:45 AM EST
Terminated Phase 4 Interventional Results available

Comparison of Nebulizers in ED in Pediatric Asthma Patients

NCT01951378
View directory record Official record
Conditions
Asthma
Interventions
Hudson RCI® nebulizer, NebuTech® HDN® nebulizer, Albuterol
Device · Drug
Lead sponsor
Seton Healthcare Family
Other
Eligibility
3 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 13, 2026, 6:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

NCT02062840
View directory record Official record
Conditions
Major Depression
Interventions
High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires
Device · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Nov 13, 2026, 6:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fasting-Mimicking Diet on Skin Health

NCT05564624
View directory record Official record
Conditions
Skin
Interventions
Fasting mimicking diet (FMD)
Other
Lead sponsor
L-Nutra Inc
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Nov 13, 2026, 6:45 AM EST
Completed Not applicable Interventional

Personalized Post-Stroke Gait Rehabilitation Interventions

NCT07212608
View directory record Official record
Conditions
Stroke
Interventions
Soft robotic exosuit, Propulsion neuroprosthesis
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Nov 13, 2026, 6:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

NCT07455825
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 13, 2026, 6:45 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Muscle Ultrasound for Sarcopenia Leading to Early Detection

NCT02319850
View directory record Official record
Conditions
Sarcopenia
Interventions
DXA scanning
Radiation
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Nov 13, 2026, 6:45 AM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease

NCT05670782
View directory record Official record
Conditions
Parkinson Disease
Interventions
KM-819, Placebo
Drug
Lead sponsor
FAScinate Therapeutics Inc.
Industry
Eligibility
40 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Glendale, California • San Diego, California • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Nov 13, 2026, 6:45 AM EST